New Scientific Advisory Board of Immuno-Inflammatory Experts
- Preliminary Topline Data for the ATI-450-RA-201 Trial Expected in
“We are looking forward to working with each of these leading experts in rheumatology and other immuno-inflammatory diseases,” said Dr.
The members of the
Aclaris also announced today that it now expects preliminary topline data for the ATI-450-RA-201 trial, its Phase 2a trial of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis, in
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding the development of Aclaris’ drug candidates, including the timing of preliminary topline data from the ATI-450-RA-201 trial. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the COVID-19 pandemic and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended
Source: Aclaris Therapeutics, Inc.